Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GDNF-inducible zinc finger protein 1 (GZF1) is a sequence-specific transcriptional repressor characterized by the presence of a BTB/POZ domain and multiple C2H2-type zinc finger motifs[1][4][5]. It is induced by glial cell line-derived neurotrophic factor (GDNF) signaling and binds a defined consensus DNA sequence (known as the GZF1 responsive element, GRE) in the regulatory regions of target genes, such as HOXA10[1]. GZF1 represses transcription by RNA polymerase II in a sequence-specific manner and likely regulates spatial and temporal gene expression during development, particularly in renal morphogenesis[1][5]. It functions primarily in the nucleus and has a role in modulating morphogenesis by acting as a negative regulator of transcription[1][4][5]. Disease associations include joint laxity, short stature, myopia, and certain forms of skeletal dysplasia[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GDNF-inducible zinc finger protein 1 (GZF1).